EGFR and Alzheimer disease: The result showed that MAPK8 significantly down-regulated, CTNNB1, NFKB1, EGFR, CXCL8, CCL2, BCL2, and NFE2L2 were significantly up-regulated in AD patients compared to controls (Figure 4).